SCHEMBL12900109

SCHEMBL12900109

O=C(Nc1ccccc1C(=O)O)c1cc(-c2ccc3c(c2)OCCO3)cs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.49
▸ MEN1 O00255 8/20 0.48
▸ KMT2A Q03164 8/20 0.48
▸ POLB P06746 4/20 0.48
▸ SMN1; SMN2 Q16637 5/20 0.48
▸ MAPT P10636 4/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ TP53 P04637 2/20 0.48
▸ FABP3 P05413 1/20 0.45
▸ FABP4 P15090 1/20 0.45
▸ FABP5 Q01469 1/20 0.45
▸ NPC1 O15118 6/20 0.45
▸ HTT P42858 1/20 0.45
▸ RAB9A P51151 5/20 0.44
▸ ADCY1 Q08828 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ DHODH Q02127 1/20 0.44
▸ HPGD P15428 2/20 0.44
▸ TSHR P16473 1/20 0.43
▸ CASP1 P29466 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12900100 0.83 HDAC6 (0.55) ALDH1A1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL12900110 0.81 RAB9A (0.52) ALDH1A1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL12900093 0.80 NPC1 (0.49) ALDH1A1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL2271243 0.77 ADCY1 (0.61) ALDH1A1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL6451894 0.76 HCAR2 (0.52) ALDH1A1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL12900103 0.76 FABP3 (0.53) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL12900086 0.75 HCAR2 (0.53) ALDH1A1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL12900087 0.74 MCL1 (0.52) ALDH1A1MEN1KMT2APOLBSMN1; SMN2
SCHEMBL12900089 0.74 FABP3 (0.50) ALDH1A1MEN1KMT2ASMN1; SMN2MAPT
SCHEMBL21313798 0.73 NPC1 (0.76) ALDH1A1MEN1KMT2APOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110028462-A1 Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2011-02-03 — — US disclosed
US-20110028462-A1 Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. 2011-02-03 — — US disclosed
WO-2007035478-A2 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2007-03-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028462-A1 Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment LDLR, APOB, FFAR1 ALDH1A1 1734/4885MEN1 2907/4885KMT2A 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback